Vertex Pharmaceuticals Proceeds from exercises of stock options and other stock issuances decreased by 50.0% to $27.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 61.7%, from $16.70M to $27.00M. Over 4 years (FY 2021 to FY 2025), Proceeds from exercises of stock options and other stock issuances shows an upward trend with a 5.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher inflows suggest robust employee participation in equity programs, which can be a sign of positive internal sentiment or high compensation utilization.
This metric captures the cash inflows received from employees and executives exercising stock options or participating i...
Commonly reported by public companies with significant equity-based compensation structures; often compared against total share-based compensation expense.
financing_proceeds_from_issuance_of_shares_under_incenti_d15335| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $37.90M | $13.80M | $34.70M | $33.70M | $64.40M | $36.60M | $51.60M | $14.20M | $58.60M | $15.40M | $46.40M | $16.90M | $55.00M | $8.40M | $34.30M | $16.70M | $49.10M | $7.90M | $54.00M | $27.00M |
| QoQ Change | — | -63.6% | +151.4% | -2.9% | +91.1% | -43.2% | +41.0% | -72.5% | +312.7% | -73.7% | +201.3% | -63.6% | +225.4% | -84.7% | +308.3% | -51.3% | +194.0% | -83.9% | +583.5% | -50.0% |
| YoY Change | — | — | — | — | +69.9% | +165.2% | +48.7% | -57.9% | -9.0% | -57.9% | -10.1% | +19.0% | -6.1% | -45.5% | -26.1% | -1.2% | -10.7% | -6.0% | +57.4% | +61.7% |